Adaptive Biotechnologies Corp. (ADPT)

Adaptive Biotechnologies' stock price has been significantly impacted by several key events over the past six months. Strong financial performance in Q4 and full-year 2025, driven by the MRD segment, led to a surge in the stock price. The stock experienced a substantial increase of 145.54% from January 10, 2025, to January 8, 2026, making it the top-performing life sciences tools and services stock in 2025. However, insiders have sold a significant amount of company stock, totaling $23,122,398.00. The company has a consensus rating of 'Moderate Buy' and an average price target of $17.11 as of January 2026.

Analysis of Adaptive Biotechnologies Corp. seasonal charts over the past five years suggests a period of seasonal strength. A 'Buy Date' of May 11 and a 'Sell Date' of August 1 has historically resulted in a geometric average return of 10.16% above the S&P 500 Total Return Index. This seasonal timeframe aligns with the broader Healthcare sector's seasonal strength, which typically runs from April 25 to December 4. However, only five years of data are available for ADPT, which may be insufficient to create a fully reliable seasonal profile.

Adaptive Biotechnologies Corporation is a biotechnology company focused on advancing immune-driven medicine. It operates within the Healthcare sector, specifically in the Biotechnology, Pharmaceuticals & Biotech, Life Sciences Tools and Services, Drug Discovery, and Oncology industries. The company's core offerings include an immunosequencing platform that combines proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data. Its major products and services include the clonoSEQ® diagnostic test, immunoSEQ®, and cellular therapy and vaccines.

Adaptive Biotechnologies Corporation is headquartered in Seattle, Washington, United States. The company primarily operates across the United States, with its principal commercial focus for clinical testing based in the U.S.

Adaptive Biotechnologies has maintained a generally positive brand reputation over the past year. This is largely driven by its strong financial performance and advancements in its core business. The preliminary Q4 and full-year 2025 revenue exceeding expectations and the accelerating adoption of its clonoSEQ diagnostic test have significantly boosted investor confidence and public perception. Being recognized as the top-performing life sciences tools and services stock in 2025 by Seeking Alpha further enhances its reputation within the industry. The company holds a 'Moderate Buy' consensus rating from analysts, indicating a favorable outlook from the financial community. The launch of clonoSEQ integration into Flatiron's OncoEMR demonstrates successful market penetration and workflow integration, which positively impacts its reputation among healthcare providers.

Adaptive Biotechnologies Corporation has significant institutional ownership. As of September 30, 2025, the company had 501 institutional owners and shareholders holding a total of 175,880,537 shares. Major institutional owners include Viking Global Investors Lp, BlackRock, Inc., and Vanguard Group Inc. Institutions hold approximately 77.6% to 99.17% of the stock, hedge funds hold around 19.3%, and individual insiders hold about 3.04% to 6.40%.